GlaxoSmithKline PLC — Regulatory Filings 2021

Feb 24, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2021

Commission File Number 001-15170

GlaxoSmithKline plc

(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

TR-1: Standard form for notification of major holdings

| NOTIFICATION OF MAJOR HOLDINGS ( to be sent
to the relevant issuer and to the FCA in Microsoft Word
format if possible) i — 1a. Identity of the issuer or the underlying issuer of existing
shares to which voting rights are attached ii : | | GlaxoSmithKline
PLC | | |
| --- | --- | --- | --- | --- |
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X"
if appropriate) | | | | |
| Non-UK issuer | | | | |
| 2. Reason for the notification (please mark the
appropriate box or boxes with an "X") | | | | |
| An
acquisition or disposal of voting rights | | | | X |
| An
acquisition or disposal of financial instruments | | | | |
| An
event changing the breakdown of voting rights | | | | |
| Other (please specify) iii : | | | | |
| 3. Details of person subject to the notification
obligation iv | | | | |
| Name | | Dodge
& Cox | | |
| City
and country of registered office (if applicable) | | San
Francisco, United States of America | | |
| 4. Full name of shareholder(s) (if different from 3.) v | | | | |
| Name | | | | |
| City
and country of registered office (if applicable) | | | | |
| 5. Date on which the threshold was crossed or
reached vi : | | 19/02/2021 | | |
| 6. Date on which issuer notified
(DD/MM/YYYY): | | 22/02/2021 | | |
| 7. Total positions of person(s) subject to the notification
obligation | | | | |
| | % of
voting rights attached to shares (total of 8. A) | %
of voting rights through financial instruments(total of
8.B 1 + 8.B 2) | Total
of both in % (8.A + 8.B) | Total
number of voting rights of issuer vii |
| Resulting
situation on the date on which threshold was crossed or
reached | 5.04% | | 5.04% | 5,031,020,062 |
| Position
of previous notification (if applicable) | | | | |

| 8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached viii | | | | | |
| --- | --- | --- | --- | --- | --- |
| A: Voting rights attached to shares | | | | | |
| Class/type ofshares ISIN
code (if possible) | Number of voting rights ix | | % of voting rights | | |
| | Direct (Art 9
of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10
of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9
of Directive 2004/109/EC) (DTR5.1) | | Indirect (Art 10
of Directive 2004/109/EC) (DTR5.2.1) |
| Ordinary GB0009252882 | | 99,377,874 | | | 1.98% |
| ADRs US37733W1053 | | 154,086,234 | | | 3.06% |
| SUBTOTAL 8. A | 253,464,108 | | 5.04% | | |
| B 1: Financial Instruments according to Art. 13(1)(a) of Directive
2004/109/EC (DTR5.3.1.1 (a)) | | | | | |
| Type of financial instrument | Expirationdate x | Exercise/Conversion Period xi | Number of voting rights that may be acquired if the instrument
is exercised/converted. | | % of voting rights |
| | | SUBTOTAL 8. B 1 | | | |
| B 2: Financial Instruments with similar economic effect according
to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1
(b)) | | | | | |
| Type of financial instrument | Expirationdate x | Exercise/Conversion Period xi | Physical or cash settlement xii | Number of voting rights | % of voting rights |
| | | | SUBTOTAL 8.B.2 | | |

| 9. Information in relation to the person subject to the
notification obligation (please mark the applicable box
with an "X") — Person
subject to the notification obligation is not controlled by any
natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer xiii | | | X |
| --- | --- | --- | --- |
| Full chain
of controlled undertakings through which the voting rights and/or
thefinancial instruments are effectively held starting with the
ultimate controlling natural person or legal entity xiv (please add additional rows as
necessary) | | | |
| Name xv | % of voting rights if it equals or is higher than the notifiable
threshold | % of voting rights through financial instruments if it equals or is
higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable
threshold |
| 10. In case of proxy voting, please identify : | | | |
| Name of
the proxy holder | | | |
| The
number and % of voting rights held | | | |
| The
date until which the voting rights will be held | | | |
| 11. Additional information xvi | | | |

| Place of completion | San
Francisco, USA |
| --- | --- |
| Date of completion | 22/02/2021 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: February
24, 2021
By:/s/ VICTORIA
WHYTE --------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc

page break